Leptin Receptor (OB Receptor or CD295 or LEPR) - Pipeline Review, H1 2016

Published: Jun, 2016 | Pages: 56 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Leptin Receptor (OB Receptor or CD295 or LEPR) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Leptin Receptor (OB Receptor or CD295 or LEPR) - Pipeline Review, H1 2016', provides in depth analysis on Leptin Receptor (OB Receptor or CD295 or LEPR) targeted pipeline therapeutics. 

The report provides comprehensive information on the Leptin Receptor (OB Receptor or CD295 or LEPR), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Leptin Receptor (OB Receptor or CD295 or LEPR) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Leptin Receptor (OB Receptor or CD295 or LEPR)
- The report reviews Leptin Receptor (OB Receptor or CD295 or LEPR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Leptin Receptor (OB Receptor or CD295 or LEPR) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Leptin Receptor (OB Receptor or CD295 or LEPR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Leptin Receptor (OB Receptor or CD295 or LEPR) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Leptin Receptor (OB Receptor or CD295 or LEPR)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Leptin Receptor (OB Receptor or CD295 or LEPR) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Leptin Receptor (OB Receptor or CD295 or LEPR) Overview 7
Therapeutics Development 8
Leptin Receptor (OB Receptor or CD295 or LEPR) - Products under Development by Stage of Development 8
Leptin Receptor (OB Receptor or CD295 or LEPR) - Products under Development by Therapy Area 9
Leptin Receptor (OB Receptor or CD295 or LEPR) - Products under Development by Indication 10
Leptin Receptor (OB Receptor or CD295 or LEPR) - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
Leptin Receptor (OB Receptor or CD295 or LEPR) - Products under Development by Companies 13
Leptin Receptor (OB Receptor or CD295 or LEPR) - Therapeutics Assessment 15
Assessment by Monotherapy/Combination Products 15
Assessment by Mechanism of Action 16
Assessment by Route of Administration 18
Assessment by Molecule Type 20
Leptin Receptor (OB Receptor or CD295 or LEPR) - Companies Involved in Therapeutics Development 22
Aegerion Pharmaceuticals, Inc. 22
Ambrx, Inc. 23
Jyant Technologies, Inc. 24
Neurotez, Inc. 25
XL-protein GmbH 26
Leptin Receptor (OB Receptor or CD295 or LEPR) - Drug Profiles 27
ARX-328 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
CV-0801 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
CV-0802 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
memtin - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
metreleptin - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Monoclonal Antibody Conjugate to Agonize Leptin Receptor for Metabolic Disorders - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Peptide to Antagonize Leptin Receptor II for Triple Negative Breast Cancer - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Recombinant Protein to Agonize Leptin Receptor for Alzheimer's Disease - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
Recombinant Protein to Agonize Leptin Receptor for Obesity - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
Synthetic Peptide to Agonize Leptin Receptor for Diabetes and Obesity - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
XL-100 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Leptin Receptor (OB Receptor or CD295 or LEPR) - Dormant Projects 43
Leptin Receptor (OB Receptor or CD295 or LEPR) - Discontinued Products 44
Leptin Receptor (OB Receptor or CD295 or LEPR) - Featured News & Press Releases 45
Feb 25, 2014: FDA approves Myalept to treat rare metabolic disease 45
Dec 12, 2013: FDA Advisory Committee votes on investigational medicine metreleptin 46
Jun 04, 2013: Bristol-Myers Squibb And AstraZeneca Receive FDA Priority Review Designation For Metreleptin 46
May 06, 2013: Bristol-Myers Squibb And AstraZeneca Announce Positive Results From Sub-Group Analysis Of Metreleptin In Pediatric Patients With Lipodystrophy 47
Aug 01, 2012: Shionogi Files New Drug Application For Recombinant Human Leptin For Lipodystrophy 48
Jul 27, 2012: Neurotez Receives US Patent 8,227,408 Covering Leptin Therapy For Alzheimer's Disease 48
Jun 25, 2012: New Clinical Data Analyses Show Amylin Pharma's Metreleptin Reduced Blood Glucose And Triglyceride Levels In Patients With Rare Forms Of Lipodystrophy 49
Apr 03, 2012: Amylin Completes Biologics License Application For Metreleptin To Treat Diabetes And/Or Hypertriglyceridemia In Patients With Rare Forms Of Lipodystrophy 50
Jun 04, 2011: Amylin's Study Results Show Treatment With Metreleptin Improves Diabetes And Lipid Control In Patients With Partial Lipodystrophy 51
Apr 15, 2011: Amylin To Present Data Showing Investigational Metreleptin Treatment Led To Long-Term Improvements In Diabetes And Lipid Control In Patients With Lipodystrophy 52
Dec 20, 2010: Amylin Submits Clinical And Nonclinical Sections Of Rolling Biologics License Application For Metreleptin To Treat Rare Forms Of Lipodystrophy 53
Nov 16, 2010: Juvenile Diabetes Research Foundation And Amylin Partner To Investigate Metreleptin As Potential Therapy To Improve Blood Glucose Control In Type 1 Diabetes 54
Appendix 55
Methodology 55
Coverage 55
Secondary Research 55
Primary Research 55
Expert Panel Validation 55
Contact Us 55
Disclaimer 56

List of Tables

Number of Products under Development for, H1 2016 8
Number of Products under Development by Therapy Area, H1 2016 9
Number of Products under Development by Indication, H1 2016 10
Comparative Analysis by Late Stage Development, H1 2016 11
Comparative Analysis by Early Stage Products, H1 2016 12
Number of Products under Development by Companies, H1 2016 13
Products under Development by Companies, H1 2016 14
Assessment by Monotherapy/Combination Products, H1 2016 15
Number of Products by Stage and Mechanism of Action, H1 2016 17
Number of Products by Stage and Route of Administration, H1 2016 19
Number of Products by Stage and Molecule Type, H1 2016 21
Pipeline by Aegerion Pharmaceuticals, Inc., H1 2016 22
Pipeline by Ambrx, Inc., H1 2016 23
Pipeline by Jyant Technologies, Inc., H1 2016 24
Pipeline by Neurotez, Inc., H1 2016 25
Pipeline by XL-protein GmbH, H1 2016 26
Dormant Projects, H1 2016 43
Discontinued Products, H1 2016 44